Engineered T cells have been shown to be highly effective in cancer immunotherapy,
although T cell exhaustion presents a challenge for their long-term function. Additional T-cell …

Achievement of immunocompetent and therapeutic T lymphopoiesis from pluripotent stem
cells (PSCs) is a central aim in T cell regenerative medicine. To date, preferentially …

The past decade has witnessed significant advances in cancer immunotherapy, particularly
through the adoptive transfer of engineered T cells in treating advanced leukemias and …

Engineered T cells are at the leading edge of clinical cell therapy. T cell therapies have had
a remarkable impact on patient care for a subset of hematological malignancies. This …

Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier
in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations …

Adoptive cell therapy (ACT) using chimeric antigen receptor (CAR) T cells holds impressive
clinical outcomes especially in patients who are refractory to other kinds of therapy …

T cells, as orchestrators of the adaptive immune response, serve important physiological
and potentially therapeutic roles, for example in cancer immunotherapy. T cells are readily …

Simple Summary Induced pluripotent stem cells (iPSCs) that can be genetically engineered
and differentiated into different types of immune cells, providing an unlimited resource for …

Immunotherapy using primary T cells has revolutionized medical care in some pathologies
in recent years, but limitations associated to challenging cell genome edition, insufficient cell …

The generation and expansion of functional T cells in vitro can lead to a broad range of
clinical applications. One such use is for the treatment of patients with advanced cancer …